Ignite Creation Date:
2024-05-05 @ 11:38 AM
Last Modification Date:
2024-10-26 @ 9:10 AM
Study NCT ID:
NCT00093964
Status:
COMPLETED
Last Update Posted:
2019-04-16
First Post:
2004-10-07
Brief Title:
Cilengitide EMD 121974 for Recurrent Glioblastoma Multiforme Brain Tumor
Sponsor:
EMD Serono
Organization:
EMD Serono
Study Overview
Official Title:
A Multicenter Open-label Randomized Uncontrolled Phase IIa Trial in Subjects With Recurrent Glioblastoma Multiforme to Investigate the Clinical Activity Safety and Tolerability of Cilengitide EMD 121974 Administered as a Single Agent
Status:
COMPLETED
Status Verified Date:
2019-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will investigate clinical activity safety and tolerability of the anti-angiogenic compound cilengitide EMD 121974 in the treatment of first recurrence of glioblastoma multiforme GBM
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None